Former Shkreli company Travere lands licensing deal with Vifor on kidney drug
Just a month ago, the biotech formerly owned by convicted drug exec Martin Shkreli saw promising data related to its kidney drug sparsentan from a 36-week treatment study. Now, Travere is putting more of its weight behind the drug with a new licensing agreement.
Travere is teaming up with the Swiss pharma Vifor in a joint collaboration and licensing agreement to commercialize sparsentan, a potential drug for FSGS and IgAN, in Europe, Australia and New Zealand.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.